We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

120 hedge funds and large institutions have $252M invested in Sutro Biopharma in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $27K | Put options by funds: $5K

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

4% more funds holding

Funds holding: 115 → 120 (+5)

2% more capital invested

Capital invested by funds: $248M → $252M (+$4.09M)

0.35% less ownership

Funds ownership: 9.31% → 8.95% (-0.35%)

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
45
Reduced
37
Closed
13
Calls
$27K
Puts
$5K
Net Calls
+$22K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.9M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$3.99M
3
EP
Eversept Partners
New York
+$3.72M
4
Millennium Management
Millennium Management
New York
+$3.05M
5
KCM
Kynam Capital Management
New Jersey
+$2.98M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$9.1M
2
FLSM
Frazier Life Sciences Management
California
-$4.96M
3
Goldman Sachs
Goldman Sachs
New York
-$2M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$1.55M
5
RCMNY
Rubric Capital Management (New York)
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Pentwater Capital Management
Florida
$1.86M +$722K +14,500 +57%
SSA
27
Schonfeld Strategic Advisors
New York
$1.66M +$51.3K +1,030 +3%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$1.63M -$356K -7,160 -17%
PAM
29
Panagora Asset Management
Massachusetts
$1.59M -$453K -9,099 -21%
OM
30
Opaleye Management
Massachusetts
$1.43M +$1.53M +30,700 New
Renaissance Technologies
31
Renaissance Technologies
New York
$1.25M +$697K +14,010 +108%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.18M +$62.6K +1,258 +5%
Man Group
33
Man Group
United Kingdom
$1.16M +$1.24M +24,867 New
DCM
34
DAFNA Capital Management
California
$1.13M +$787K +15,808 +187%
Adage Capital Partners
35
Adage Capital Partners
Massachusetts
$1.05M +$846K +17,000 +305%
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$995K +$1.07M +21,402 New
N
37
Nuveen
North Carolina
$993K -$124K -2,484 -10%
Point72 Asset Management
38
Point72 Asset Management
Connecticut
$972K +$1.04M +20,900 New
Fisher Asset Management
39
Fisher Asset Management
Washington
$914K +$978K +19,652 New
Morgan Stanley
40
Morgan Stanley
New York
$882K +$225K +4,518 +31%
Charles Schwab
41
Charles Schwab
California
$748K +$74.4K +1,494 +10%
Jane Street
42
Jane Street
New York
$679K +$727K +14,596 New
Russell Investments Group
43
Russell Investments Group
United Kingdom
$636K -$15.1K -303 -2%
Two Sigma Investments
44
Two Sigma Investments
New York
$632K -$1.02M -20,459 -60%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$628K -$114K -2,286 -14%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$617K +$65.7K +1,320 +11%
Ameriprise
47
Ameriprise
Minnesota
$584K -$20K -402 -3%
SAM
48
Simplify Asset Management
Nevada
$558K – – –
TI
49
Trexquant Investment
Connecticut
$477K -$400K -8,031 -44%
TCM
50
Tekla Capital Management
Massachusetts
$457K – – –
1
2
3 4 5

STRO Hedge Fund Activity: Q2 2023 in Review

120 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2023, worth a combined $252M — up 1.7% from $248M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new STRO positions and 13 closed out — a net gain of 5 holders — while 45 added to existing stakes and 37 trimmed.

The largest buyer was BlackRock, adding an estimated $4.9M. The largest seller was State Street, cutting an estimated $9.1M.

  • 120 institutional investors held Sutro Biopharma (STRO) as of Q2 2023, up from 115 in Q1 2023.
  • Funds reported $252M of Sutro Biopharma stock for Q2 2023, up 1.7% quarter-over-quarter.
  • 18 funds opened new Sutro Biopharma positions in Q2 2023 and 13 closed out, a net change of +5 holders.
  • The largest Sutro Biopharma buyer in Q2 2023 was BlackRock, an estimated $4.9M added.
  • The largest Sutro Biopharma seller in Q2 2023 was State Street, an estimated $9.1M sold.

Based on aggregated 13F filings for Q2 2023.